SensID Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
15
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
3
SensID General Information
Description
Manufacturer of biotechnology reference materials and quality controls designed for molecular diagnostics with a focus on oncology and precision medicine. The company's platform specializes in research and development, instrument validation, external control, accreditation preparation, proficiency testing, and conformity assessment in full compliance with the relevant quality, enabling clients to improve patient outcomes and reduce costs.
Contact Information
Website
www.sens-id.com(Operating Subsidiary)
Corporate Office
- Schillingallee 68
- 18057 Rostock
- Germany
Corporate Office
- Schillingallee 68
- 18057 Rostock
- Germany
SensID Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
SensID Comparisons
Industry
Financing
Details
SensID Competitors (2)
One of SensID’s 2 competitors is Horizon Discovery, a Formerly VC-backed company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Horizon Discovery | Formerly VC-backed | Cambridge, United Kingdom | ||||
| Horizon Pharma (primary care unit) | Failed Transaction (M&A) |
SensID Patents
SensID Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4720329-A1 | Reference material comprising nucleic acids having a fragmentation and nucleosome profile and diagnostic method | Pending | 26-May-2023 | ||
| US-20260347927-A1 | Reference material comprising nucleic acids having a fragmentation and nucleosome profile and diagnostic method | Pending | 26-May-2023 | ||
| WO-2024246014-A1 | Reference material comprising nucleic acids having a fragmentation and nucleosome profile and diagnostic method | Inactive | 26-May-2023 | ||
| EP-4467659-A1 | Reference material comprising nucleic acids with a fragmentation and nucleosome profile and diagnosis | Inactive | 26-May-2023 | ||
| EP-4123033-A1 | Blood matrix as reference material for in vitro diagnosis | Inactive | 21-Jul-2021 | C12Q1/6806 |
SensID Signals
SensID Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
SensID FAQs
-
When was SensID founded?
SensID was founded in 2015.
-
Where is SensID headquartered?
SensID is headquartered in Rostock, Germany.
-
What is the size of SensID?
SensID has 15 total employees.
-
What industry is SensID in?
SensID’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is SensID a private or public company?
SensID is a Private company.
-
What is SensID’s current revenue?
The current revenue for SensID is .
-
Who are SensID’s investors?
GENIUS Venture Capital and OstseeSparkasse Rostock have invested in SensID.
-
Who are SensID’s competitors?
Horizon Discovery and Horizon Pharma (primary care unit) are competitors of SensID.
-
When was SensID acquired?
SensID was acquired on 06-Nov-2024.
-
Who acquired SensID?
SensID was acquired by Microbiologics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process